14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CBIO vs OKUR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CBIO vs OKUR. Trailing 12-month operating profitability (CBIO -1228.4% vs OKUR 0.0%) and valuation multiples (CBIO N/M vs OKUR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CBIO vs OKUR Key Questions & Quantitative Answers
As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CBIO carries a Unified Composite Score of 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.1); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CBIO leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with OKUR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CBIO generates $15M in USD-normalized revenue versus N/A for OKUR. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKUR.
CBIO screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin), whereas OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus OKUR (-55.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk). By comparison, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.